CONTROVERSIES IN UROLOGY: Edited by Shahrokh F. ShariatAn up-to-date catalogue of urinary markers for the management of prostate cancerBrönimann, Stephana; Pradere, Benjamina,b; Karakiewicz, Pierrec; Huebner, Nicolai A.a; Briganti, Albertod; Shariat, Shahrokh F.a,e,f,g,h,i,j,kAuthor Information aDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria bDepartment of Urology, CHRU Tours, Francois Rabelais University, Tours, France cCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada dDepartment of Urology and Division of Experimental Oncology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy eDivision of Urology, Department of Special Surgery, Jordan University Hospital, The 2 University of Jordan, Amman, Jordan fDepartments of Urology, Weill Cornell Medical College, New York, New York gDepartment of Urology, University of Texas Southwestern, Dallas, Texas, USA hDepartment of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic iInstitute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia jEuropean Association of Urology research foundation, Arnhem, the Netherlands kKarl Landsteiner Institute of Urology and Andrology, Vienna Correspondence to Shahrokh F. Shariat, Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. Tel: +43 14040026150; e-mail: email@example.com Current Opinion in Urology: September 2020 - Volume 30 - Issue 5 - p 684-688 doi: 10.1097/MOU.0000000000000807 Buy Metrics Abstract Purpose of review Prostate cancer (PCa) is the most commonly diagnosed cancer in men. Poor specificity and sensitivity of total PSA often results in over and sometimes underdetection/treatment. Therefore, more specific and sensitive biomarkers for the detection and monitoring especially of clinically significant PCa as well as treatment-specific markers are much sought after. In this field, urine has emerged as a promising noninvasive source of biomarkers. Recent findings RNA-based biomarkers are the most extensively studied type of urinary nucleic acids. ERG-Score/MiPS (Mi-Prostate Score) and SelectMDx might be considered as additional parameters together with clinical and imaging modalities to decrease unnecessary biopsies. miR Sentinel Tests could make it possible to accurately detect the presence of cancer and to distinguish low-grade from high-grade disease. In men with previous negative biopsies, PCA3 may suggest the need to repeat biopsy. Summary The definitive role of these markers and their clinical benefit needs future validation. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.